Bank of New York Mellon Corp Has $9.62 Million Stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Bank of New York Mellon Corp cut its stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) by 6.5% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 437,515 shares of the life sciences company's stock after selling 30,447 shares during the period. Bank of New York Mellon Corp owned approximately 0.57% of Integra LifeSciences worth $9,621,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of IART. Principal Financial Group Inc. grew its holdings in shares of Integra LifeSciences by 2.5% during the first quarter. Principal Financial Group Inc. now owns 433,924 shares of the life sciences company's stock valued at $9,542,000 after buying an additional 10,492 shares in the last quarter. Teacher Retirement System of Texas purchased a new position in shares of Integra LifeSciences during the first quarter valued at $223,000. Wealth Enhancement Advisory Services LLC purchased a new position in shares of Integra LifeSciences during the first quarter valued at $251,000. Assenagon Asset Management S.A. grew its holdings in shares of Integra LifeSciences by 2,418.7% during the first quarter. Assenagon Asset Management S.A. now owns 1,799,944 shares of the life sciences company's stock valued at $39,581,000 after buying an additional 1,728,480 shares in the last quarter. Finally, Handelsbanken Fonder AB grew its holdings in shares of Integra LifeSciences by 22.5% during the first quarter. Handelsbanken Fonder AB now owns 28,902 shares of the life sciences company's stock valued at $636,000 after buying an additional 5,300 shares in the last quarter. 84.78% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Stock Performance

Shares of NASDAQ IART traded up $0.40 during trading hours on Friday, hitting $13.11. 956,448 shares of the company's stock were exchanged, compared to its average volume of 953,432. Integra LifeSciences Holdings Corporation has a 1-year low of $11.06 and a 1-year high of $32.19. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.21 and a quick ratio of 0.72. The stock has a market capitalization of $1.02 billion, a price-to-earnings ratio of -34.50, a PEG ratio of 0.71 and a beta of 1.15. The company's 50-day moving average price is $12.61 and its 200-day moving average price is $17.99.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The life sciences company reported $0.41 earnings per share for the quarter, missing the consensus estimate of $0.43 by ($0.02). Integra LifeSciences had a positive return on equity of 12.12% and a negative net margin of 1.78%. The business had revenue of $382.65 million for the quarter, compared to analyst estimates of $381.17 million. During the same period in the prior year, the firm posted $0.55 EPS. Integra LifeSciences's revenue for the quarter was up 3.7% on a year-over-year basis. On average, sell-side analysts expect that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on IART. Argus upgraded Integra LifeSciences from a "hold" rating to a "buy" rating in a report on Monday, March 31st. Wells Fargo & Company lowered their target price on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. JMP Securities cut their price target on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a research note on Friday, May 9th. Truist Financial cut their price objective on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a research report on Tuesday, May 6th. Four analysts have rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $18.63.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.